• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Capecitabine Teva
    / Abic

    Active Ingredient
    Capecitabine 150 mg, 500 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    60 X 150 mg

    partial basket chart 57488 9774

    Film Coated Tablets

    120 X 500 mg

    partial basket chart 57489 9775


    This product should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic medicinal products. Careful monitoring during the first cycle of treatment is recommended for all patientsPlease refer to the license holder for further details.


    Adjuvant Colon Cancer: For the adjuvant treatment of patients following surgery of stage III (Dukes stage C) colon cancer.
    Colorectal Cancer: Treatment of patients with advanced or metastatic colorectal cancer.
    Advanced gastric cancer: 1st line treatment of advanced gastric cancer in combination with chemotherapy.
    Breast Cancer Combination Therapy: In combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
    Breast Cancer Monotherapy: Treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.


    History of severe and unexpected reactions to fluoropyrimidine therapy. Hypersensitivity to capecitabine or to any of the excipients, or fluorouracil. In patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. During pregnancy and lactation. In patients with severe leukopenia, neutropenia, or thrombocytopenia. In patients with severe hepatic impairment. In patients with severe renal impairment (creatinine clearance below 30 ml/min). Treatment with sorivudine or its chemically related analogues, such as brivudine If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used.